Cadila receives USFDA approval for Carbamazepine extended-release tablets

The company will manufacture the drug at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Feb 08, 2019 12:02 IST India Infoline News Service

Cadila Healthcare
Cadila Healthcare, in its press note to the exchanges on Friday, informed that the company has received approval from the USFDA to market Carbamazepine Extended-Release Tablets USP (US RLD-Tegretol XR), 100 mg, 200 mg, and 400 mg.

The company will manufacture the drug at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

"Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity. This medication is used to treat certain types of seizures (partial, generalized tonic-clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia)," the company added.

Cadila Healthcare Ltd's share price is currently at Rs323.50, up by Rs1.65 or 0.51%, from its previous close of Rs321.85 on the BSE.
The scrip opened at Rs328.40 and has touched a high and low of Rs328.40 and Rs320, respectively. So far 11,82,684 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs32,949.16cr.

Related Story